MX2022001412A - Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona. - Google Patents

Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona.

Info

Publication number
MX2022001412A
MX2022001412A MX2022001412A MX2022001412A MX2022001412A MX 2022001412 A MX2022001412 A MX 2022001412A MX 2022001412 A MX2022001412 A MX 2022001412A MX 2022001412 A MX2022001412 A MX 2022001412A MX 2022001412 A MX2022001412 A MX 2022001412A
Authority
MX
Mexico
Prior art keywords
compounds
azepine
pyrazolo
dihydro
ch2ch3
Prior art date
Application number
MX2022001412A
Other languages
English (en)
Inventor
Amador Wenceslao Lumeras
Barbara Jean Brandhuber
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022001412A publication Critical patent/MX2022001412A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En el presente documento se describen compuestos de Fórmula I: (ver Fórmula) en la que R1 es -CH3 o -CH2CH3; y sales farmacéuticamente aceptables de estos, que son útiles para tratar el cáncer.
MX2022001412A 2019-08-05 2020-08-03 Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona. MX2022001412A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382680 2019-08-05
PCT/US2020/044718 WO2021026059A1 (en) 2019-08-05 2020-08-03 7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS

Publications (1)

Publication Number Publication Date
MX2022001412A true MX2022001412A (es) 2022-03-25

Family

ID=67551324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001412A MX2022001412A (es) 2019-08-05 2020-08-03 Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona.

Country Status (14)

Country Link
US (1) US20220251096A1 (es)
EP (1) EP4010343B1 (es)
JP (1) JP7293493B2 (es)
KR (1) KR20220029735A (es)
CN (1) CN114269750A (es)
AR (1) AR119557A1 (es)
AU (1) AU2020324949B2 (es)
BR (1) BR112022000036A2 (es)
CA (1) CA3145651A1 (es)
ES (1) ES2963582T3 (es)
IL (1) IL289141A (es)
MX (1) MX2022001412A (es)
TW (1) TW202120095A (es)
WO (1) WO2021026059A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6820254B2 (ja) 2014-10-10 2021-01-27 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
JP6771464B2 (ja) 2014-11-27 2020-10-21 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
CN115028617A (zh) 2016-05-24 2022-09-09 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
CN109476663B (zh) 2016-05-24 2021-11-09 基因泰克公司 用于治疗癌症的吡唑并吡啶衍生物
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物

Also Published As

Publication number Publication date
JP7293493B2 (ja) 2023-06-19
EP4010343A1 (en) 2022-06-15
US20220251096A1 (en) 2022-08-11
WO2021026059A1 (en) 2021-02-11
AU2020324949A1 (en) 2022-01-20
AR119557A1 (es) 2021-12-29
KR20220029735A (ko) 2022-03-08
JP2022543277A (ja) 2022-10-11
ES2963582T3 (es) 2024-04-01
BR112022000036A2 (pt) 2022-04-26
AU2020324949B2 (en) 2023-11-02
IL289141A (en) 2022-02-01
TW202120095A (zh) 2021-06-01
CN114269750A (zh) 2022-04-01
CA3145651A1 (en) 2021-02-11
EP4010343B1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
AU2019231551A8 (en) Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones
MX2022006986A (es) Inhibidores de kras g12c.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2021000309A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-dion a y su uso en el tratamiento de enfermedades dependientes del dedo de zinc 2 de la familia ikaros (ikzf2).
CR20220354A (es) Inhibidores de egfr
MX2023001876A (es) Derivados de rapamicina.
MX2020007392A (es) Compuestos de benzamida.
MX2023010411A (es) Inhibidores de erbb/btk.
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
MX2021011606A (es) Compuestos dirigidos a prmt5.
CR20210626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2023004373A (es) Metodos y composiciones para la degradacion dirigida de proteinas.
MX2022009059A (es) Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MX2022000939A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
MX2021009206A (es) Terapias contra el cancer.
MX2022001412A (es) Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona.